UK Blood Cancer Research Network

Welcome to the UK Blood Cancer Research Network (UKBCRN). As a member of the UK Collaborative for Cancer Clinical Research (UK3CR), the UKBCRN will ensure that the UK is a world leader in the development and conduct of cancer clinical research. The network provides strategic oversight of the blood cancer clinical research portfolio, identifying and setting research priority areas, as well as providing a platform for collaboration, capacity building and coordination between the UK and international groups and industry.

The overarching aim of the Network is to improve outcomes for people with blood cancer by:

• Facilitating participation in clinical trials through both:
  • development of new high-quality clinical trials for funding applications and
  • supporting UK and global trials delivery within the UK where appropriate.
• Producing high-quality practice-changing research outputs resulting from the Network’s activities.

The UKBCRN Steering Committee sets the strategy and has oversight of UKBCRN activity.

It comprises:

• Professor Gordon Cook (Chair, Haemato-Oncology Research Group)
• Professor Mhairi Copland (Vice Chair, Haemato-Oncology Research Group)
• Professor Andrew Davies (Chair, Lymphoma Research Group)
• Professor Christopher Fox (Vice Chair, Lymphoma Research Group)
• Dr Rubina Ahmed (Blood Cancer UK, Director of Research, Policy and Services)
• Patient Advocate Lead representatives
• Early Career Researcher Lead representatives

Each Research Group has several study groups that develop research in areas of strategic need.

Management groups
Two management groups have operational oversight for both the Haemato-Oncology and Lymphoma Research Group. These comprise study group Chairs and Vice Chairs, patient advocate lead and early career researcher lead representatives.

The UKBCRN’s terms of reference can be found here:

If you would like to join a study group or working group please contact [email protected] or complete this form.